Viking's VK2735 maintenance data remains the quarter's outstanding small-cap readout

Viking Therapeutics is running a Phase 1 study testing maintenance-dosing strategies for subcutaneous VK2735, its GLP-1/GIP dual agonist for obesity, and the data are guided to arrive in the third quarter of 2026 ^[1]. Industry tracker ObesityIntel calls the readout "the quarter's outstanding small-cap catalyst," noting it will show "whether weight loss holds at a lower maintenance dose" and describing it as a preview of Viking's larger Phase 3 program ^[1].

The study design starts patients on weekly induction dosing, then switches them to less frequent regimens — either monthly injections or an oral form of the drug — to see whether the weight loss holds up over time ^[1]. Viking's own description of its pipeline confirms VK2735 "is currently being evaluated in Phase 3 clinical studies for obesity, along with maintenance dosing strategies designed to support long-term weight management" ^[2].

Earlier-stage data give some sense of the drug's ceiling. The subcutaneous formulation has produced weight loss of up to 14.7% over 13 weeks, and the oral version up to 12.2% over the same period, according to ObesityIntel's pipeline tracker ^[1]. Those numbers came from studies that predate the maintenance-dosing question now being tested. Specific results on how much weight patients keep off during maintenance dosing were not available in the sources reviewed for this story, so it is not yet known how the maintenance regimens compare with the earlier induction-phase numbers.

Viking ended the second quarter of 2026 with $502 million in cash, giving it a runway into 2028, according to ObesityIntel's company profile ^[1]. The company has been meeting with investors this month, including a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14 and another at the Bernstein 3rd Annual Healthcare Forum on September 23, alongside an earlier appearance at the Cantor Global Healthcare Conference on September 11 ^[2].

Why it matters for patients

Weekly injections are a known burden for people managing obesity long term, so a monthly shot or a pill that preserves the same weight loss could make treatment easier to stick with if the data hold up. That is the practical question this study is meant to answer: not whether VK2735 works, but whether patients can step down to a less frequent, more convenient regimen without regaining weight.

It is also worth being clear about what is not yet known. The maintenance-dosing results have not been published, so there is no confirmed figure yet for how much weight loss is retained on the lower-frequency regimens. VK2735 is not approved for use in the United States. It remains in clinical testing, and ObesityIntel frames the decisive test for the drug as the Phase 3 VANQUISH-1 trial, not this quarter's maintenance data ^[1].

What happens next

The maintenance-dosing results are guided for the third quarter of 2026 ^[1]. The larger and more consequential readout is VANQUISH-1, a Phase 3 trial enrolling roughly 4,650 patients over 78 weeks, whose topline results are not expected until late 2027 ^[1]. ObesityIntel describes that trial as "the main binary event" for Viking, saying success would lift VK2735 "close to the market leaders" — a reference to tirzepatide (Zepbound/Mounjaro) and semaglutide (Wegovy/Ozempic) — while failure "erases much of the thesis" behind the company ^[1]. In the meantime, Viking continues its round of investor conference appearances through late September ^[2].